FDA-approved mAbs for use in oncology
| Name | Marketed by | Class | Target | First approved indication | Reported mechanisms of action | Approval year |
|---|---|---|---|---|---|---|
| Rituximab (Rituxan) | Biogen Idec/ Genentech | Chimeric IgG1 | CD20 | Non-Hodgkin’s Lymphoma | ADCC, CDC, Induction of Apoptosis4 | 1997 |
| Trastuzumab (Herceptin) | Genentech | Humanized IgG1 | HER2 | Breast Cancer | Signal Inhibition, ADCC5 | 1998 |
| Alemtuzumab (Campath) | Sanofi-Aventis | Humanized IgG1 | CD52 | B cell Chronic Lymphocytic Leukemia | CDC, Induction of Apoptosis6 | 2001 |
| Ibritumomab tiuxetan (Zevalin) | Biogen Idec | Murine IgG1 | CD20 | Non-Hodgkin’s Lymphoma | Radioisotope Delivery (90Y) | 2002 |
| Tositumomab (Bexxar) | GlaxoSmithKline | Murine IgG2a | CD20 | Non-Hodgkin’s Lymphoma | Radioisotope Delivery (131I), ADCC, CDC, Induction of Apoptosis7 | 2003 |
| Cetuximab (Erbitux) | Bristol-Myers Squibb/Eli Lilly | Chimeric IgG1 | EGFR | Squamous Cell Carcinoma of the Head and Neck | Signal Inhibition, ADCC, CDC8 | 2004 |
| Bevacizumab (Avastin) | Genentech | Humanized IgG1 | VEGF | Colorectal Cancer | Signal Inhibition9 | 2004 |
| Panitumumab (Vectibix) | Amgen | Human IgG2 | EGFR | Colorectal Cancer | Signal Inhibition, ADCC10 | 2006 |
| Ofatumumab (Arzerra) | Genmab/GSK | Human IgG1 | CD20 | Chronic Lymphocytic Leukemia | ADCC, CDC11 | 2009 |
| Denosumab (Xgeva) | Amgen | Human IgG2 | RANKL | Bone Metastases | Signal Inhibition | 2010 |
| Ipilimumab (Yervoy) | Bristol-Myers Squibb | Human IgG1 | CTLA-4 | Metastatic Melanoma | Signal Inhibition12 | 2011 |
| Brentuximab vedotin (Adcetris) | Seattle Genetics | Chimeric IgG1 | CD30 | Hodgkin Lymphoma | ADC | 2011 |
| Pertuzumab (Perjeta) | Genentech | Humanized IgG1 | HER2 | Breast Cancer | Signal Inhibition, ADCC13 | 2012 |
| Trastuzumab emtansine (Kadcyla) | Genentech | Humanized IgG1 | HER2 | Breast Cancer | ADC, Signal Inhibition, ADCC14 | 2013 |